The Food and Drug Administration-approved antipsychotic drug trifluoperazine, a calmodulin antagonist, inhibits viral replication through PERK-eIF2α axis

The Food and Drug Administration-approved antipsychotic drug trifluoperazine, a calmodulin antagonist, inhibits viral replication through PERK-eIF2α axis

Virus-related diseases are seriously threatening human health, but there are currently only 10 viruses with clinically approved antiviral drugs available. As non-cellular organisms, viruses parasitize in living cells and rely on the protein synthesis mechanism of the host cells. In this study, we fo...

Full description

Bibliographic Details
Main Authors: Yizhi Mao, Ziyang Wang, Chen Yao, Qi Zeng, Wei Cheng, Shimeng Zhang, Shuai Chen, Chunjie Sheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Microbiology
Subjects:
trifluoperazine
antiviral drugs
eIF2α
PKR-like endoplasmic reticulum kinase (PERK)
calmodulin
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2022.979904/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2022.979904/full

Similar Items